Tofacitinib: a successful treatment option for SAPHO syndrome

International Journal of DermatologyEarly View Clinical correspondence Tofacitinib: a successful treatment option for SAPHO syndrome Sezgi Sarikaya Solak, Corresponding Author Sezgi Sarikaya Solak [email protected] orcid.org/0000-0002-8572-8249 Faculty of Medicine, Department of Dermatology, Trakya University, Edirne, TurkeySearch for more papers by this authorHande Yelgen Ilyas, Hande Yelgen Ilyas Faculty of Medicine, Department of Dermatology, Trakya University, Edirne, TurkeySearch for more papers by this author Sezgi Sarikaya Solak, Corresponding Author Sezgi Sarikaya Solak [email protected] orcid.org/0000-0002-8572-8249 Faculty of Medicine, Department of Dermatology, Trakya University, Edirne, TurkeySearch for more papers by this authorHande Yelgen Ilyas, Hande Yelgen Ilyas Faculty of Medicine, Department of Dermatology, Trakya University, Edirne, TurkeySearch for more papers by this author First published: 15 February 2024 https://doi.org/10.1111/ijd.17075 Conflict of interest: None. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1Chen W, Ito T, Lin SH, Song Z, al-Khuzaei S, Jurik AG, et al. Does SAPHO syndrome exist in dermatology? J Eur Acad Dermatol Venereol. 2022; 36(9): 1501–1506. 10.1111/jdv.18172 CASPubMedWeb of Science®Google Scholar 2Cheng W, Li F, Tian J, Xie X, Chen JW, Peng XF, et al. New insights in the treatment of SAPHO syndrome and medication recommendations. J Inflamm Res. 2022; 15: 2365–2380. 10.2147/JIR.S353539 CASPubMedWeb of Science®Google Scholar 3Yang Q, Zhao Y, Li C, Luo Y, Hao W, Zhang W. Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib. Medicine (Baltimore). 2018; 97(25):e11149. 10.1097/MD.0000000000011149 PubMedWeb of Science®Google Scholar 4Li B, Li GW, Xue L, Chen YY. Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: a case report. World J Clin Cases. 2020; 8(19): 4527–4534. 10.12998/wjcc.v8.i19.4527 PubMedWeb of Science®Google Scholar 5Luan L, Lv C. Secukinumab-induced paradoxical skin lesions, but successful treatment with tofacitinib in SAPHO syndrome: a case report. J Dermatol Treat. 2023; 34(1):2193662. 10.1080/09546634.2023.2193662 PubMedWeb of Science®Google Scholar 6Yuan F, Luo J, Yang Q. SAPHO syndrome complicated by ankylosing spondylitis successfully treated with tofacitinib: a case report. Front Immunol. 2022; 13:911922. 10.3389/fimmu.2022.911922 CASPubMedWeb of Science®Google Scholar 7Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther. 2023; 13(3): 729–749. 10.1007/s13555-023-00892-5 Google Scholar 8LaBranche TP, Jesson MI, Radi ZA, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012; 64(11): 3531–3542. 10.1002/art.34649 CASPubMedWeb of Science®Google Scholar 9Xie W, Huang H, Zhang Z. Off-label use of tofacitinib: a potential treatment option for SAPHO syndrome. Ann Rheum Dis. 2022; 81(6):e91. 10.1136/annrheumdis-2020-217854 PubMedWeb of Science®Google Scholar 10Liu S, Li C, Tang MW, Xu WS, Chen KQ, Sui X, et al. Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome. Chin Med J. 2019; 132(19): 2378–2379. 10.1097/CM9.0000000000000441 PubMedWeb of Science®Google Scholar 11Liu S, Tang M, Cao Y, Li C. Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: review and update. Ther Adv Musculoskelet Dis. 2020; 12:1759720x20912865. 10.1177/1759720X20912865 PubMedWeb of Science®Google Scholar 12Li Y, Huo J, Cao Y, Yu M, Zhang Y, Li Z, et al. Efficacy of tofacitinib in synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a pilot study with clinical and MRI evaluation. Ann Rheum Dis. 2020; 79(9): 1255–1257. 10.1136/annrheumdis-2020-217250 PubMedWeb of Science®Google Scholar 13Liu Y, Wu X, Cao Y, Liu S, Ma M, Li C. Synovitis, acne, pustulosis, hyperostosis and osteitis syndrome with mandibular involvement: would surgical operation help? Int J Rheum Dis. 2023; 26(3): 563–567. 10.1111/1756-185X.14542 CASPubMedWeb of Science®Google Scholar 14Wang R, Li Y, Liu Y, Hou X, Li C. Synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome with Henoch-Schönlein purpura: a case report. Clin Cosmet Investig Dermatol. 2023; 16: 1089–1094. 10.2147/CCID.S392909 PubMedWeb of Science®Google Scholar 15Cao F, Hou X, Kang T, Shi X, Ma W, Zhang Y, et al. SAPHO syndrome complicated with relapsing polychondritis: a case report. Int J Rheum Dis. 2023; 26: 2060–2063. 10.1111/1756-185X.14693 PubMedWeb of Science®Google Scholar 16Baisya R, Gavali M, Tyagi M, Devarasetti PK. A case of SAPHO syndrome complicated by uveitis with good response to both TNF inhibitor and JAKinib. Case Rep Rheumatol. 2023; 2023:6201887. PubMedGoogle Scholar 17Li C, Li Z, Cao Y, Li L, Li F, Li Y, et al. Tofacitinib for the treatment of nail lesions and palmoplantar pustulosis in synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome. JAMA Dermatol. 2021; 157(1): 74–78. 10.1001/jamadermatol.2020.3095 PubMedWeb of Science®Google Scholar 18Ru C, Qian T, Liu X, Wang C, Li W, Hou X, et al. SAPHO syndrome with Takayasu arteritis successfully treated with tofacitinib. Int J Rheum Dis. 2023; 26(7): 1381–1383. 10.1111/1756-185X.14628 PubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation